Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Bergamo – page 44

2 770 clinical trials in Bergamo, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bergamo at a glance
2 770
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 770 trials in Bergamo

Open in trial search

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:ECRI-trials B.V.

Acarodermatitis

Recruiting

Comparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Giuliani S.p.A.

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navlimetostat
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Bergamo

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure prevention and cardiovascular disease. Studies include evaluation of novel drug combinations and therapies for patients with elevated cardiovascular risks.

  • Heart Failure Prevention
  • Myocardial Infarction Treatment
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive research focusing on various cancer types, including non-small cell lung cancer and prostate cancer. Studies evaluate innovative treatment approaches combining immunotherapy with traditional methods.

  • Lung Cancer Therapies
  • Prostate Cancer Treatment
  • Breast Cancer Research
03 Rare Diseases

Specialized trials investigating treatments for conditions like Alagille syndrome and amyotrophic lateral sclerosis. Research focuses on improving patient outcomes and quality of life.

  • Genetic Disorders
  • Neurological Conditions
  • Rare Blood Disorders
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.